Fibrogen Inc Stock Price, News & Analysis

FibroGen announced that CEO Enrique Conterno will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 3:40 PM ET. The event's live audio webcast will be accessible on the FibroGen Investor webpage, with a replay available for about 30 days. FibroGen focuses on developing first-in-class therapeutics, including Pamrevlumab, for treating conditions like idiopathic pulmonary fibrosis and pancreatic cancer. Their Roxadustat is already approved for treating anemia in CKD patients and is in further clinical trials.

FibroGen, Inc. (NASDAQ: FGEN) will have CEO Enrique Conterno participate in a fireside chat at the Bank of America 2022 Biotech SMID Cap Virtual Conference on December 8 at 1:05 PM Eastern Time. Investors can access a live audio webcast on the company's Investors webpage, with a replay available for 30 days. FibroGen focuses on developing first-in-class therapeutics, including treatments for idiopathic pulmonary fibrosis, pancreatic cancer, and anemia. Notably, Roxadustat is approved in multiple countries for CKD anemia and is in advanced trials for related conditions.

FibroGen (FGEN) reported a third-quarter 2022 net loss of $91.7 million, translating to $0.98 per share, compared to a net income of $49.8 million during the same period last year. Total revenue fell to $15.7 million from $156.0 million, impacted by a 2021 milestone payment from Astellas. However, the company secured $50 million through a non-dilutive royalty monetization deal with NovaQuest, backed by 22.5% of roxadustat royalty revenue. Roxadustat sales in China grew 29% to $17.4 million, while the MATTERHORN Phase 3 study for MDS has completed enrollment, with topline data expected in 1H 2023.

FibroGen, Inc. (FGEN) announced a strategic financing partnership with NovaQuest Capital Management, securing $50 million in non-dilutive capital. This funding aims to support the company's growth and innovation, particularly for EVRENZO™ and its late-stage pipeline. FibroGen will allocate part of the proceeds towards its pamrevlumab program, anticipating multiple pivotal Phase 3 readouts in 2023 and 2024. The agreement grants NovaQuest 22.5% of future EVRENZO™ royalties in certain regions until capped payments are reached, after which FibroGen retains full royalty rights.

FibroGen (NASDAQ: FGEN) announces that CEO Enrique Conterno will participate in a fireside chat at the Stifel 2022 Healthcare Conference in New York on November 15, 2022, at 1:50 PM ET. A live audio webcast will be accessible via the Investors section of the FibroGen website, with a replay available for 30 days.

FibroGen is a biopharmaceutical company focused on innovative therapies, including the clinical development of Pamrevlumab for treating various conditions and Roxadustat, which is approved internationally for anemia in CKD patients.

FibroGen, Inc. (NASDAQ: FGEN) will release its third quarter 2022 financial results on November 7, 2022, after market close. The company will also host a conference call with investors at 5:00 p.m. ET to discuss its corporate and financial performance. FibroGen focuses on developing innovative therapeutics, including the anti-CTGF monoclonal antibody, Pamrevlumab, and the anemia treatment, Roxadustat, which is already approved in several countries. The company is expanding its research into immuno-oncology and autoimmune therapies.

FibroGen has announced the successful completion of patient enrollment in the MATTERHORN, a Phase 3 clinical study evaluating roxadustat for treating anemia in 141 patients with lower risk transfusion-dependent myelodysplastic syndromes (MDS). This double-blind, placebo-controlled study aims to assess transfusion independence over 28 weeks, with top-line data expected in the first half of 2023. MDS affects over 80% of diagnosed patients, highlighting the need for effective treatment options. Roxadustat, already approved in several regions for anemia in chronic kidney disease, demonstrates potential in revising MDS treatment.

FibroGen reported a 22% revenue increase in Q2 2022, totaling $29.8 million compared to $24.4 million in the same quarter last year. The company completed enrollment for the LELANTOS-2 Phase 3 trial of pamrevlumab in ambulatory DMD patients. Notably, roxadustat sales in China reached $53.1 million, marking a considerable jump in volume. However, the net loss for the quarter was $72.6 million, an improvement from a loss of $134.0 million a year ago. FibroGen expects topline data from multiple pivotal trials in 2023.

FibroGen, Inc. (NASDAQ: FGEN) will release its Q2 2022 financial results on August 8 after market close. The company will also hold a conference call at 5:00 p.m. ET to discuss its corporate and financial performance with investors. FibroGen is known for developing innovative therapeutics, including pamrevlumab for idiopathic pulmonary fibrosis, and roxadustat for various types of anemia. They have recently expanded their R&D portfolio into immuno-oncology and autoimmune therapies.